STOCK TITAN
  1. Home
  2. Sec-filings
  3. AXGN
  4. [Form 4] Axogen, Inc. Insider Trading Activity

Axogen (AXGN) director John Johnson receives 4,392 RSUs valued at $185,000

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

JOHNSON JOHN reported acquisition or exercise transactions in this Form 4 filing.

Axogen, Inc. director John Johnson received an annual equity grant of 4,392 restricted stock units (RSUs) as compensation for serving on the Board of Directors. Each RSU represents a contingent right to receive one share of Axogen common stock. The award is based on a $185,000 valuation as of the grant date and is scheduled to vest on June 24, 2027, the one-year anniversary of the grant date, subject to the stated service conditions.

Positive

  • None.

Negative

  • None.
Insider JOHNSON JOHN
Role null
Type Security Shares Price Value
Grant/Award Restricted Stock Units 4,392 $0.00 --
Holdings After Transaction: Restricted Stock Units — 4,392 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.
RSUs granted 4,392 units Annual equity grant to director John Johnson
Grant valuation $185,000 Valuation as of the grant date for the RSU award
Post-grant RSU holdings 4,392 units Total restricted stock units following the transaction
Underlying common shares 4,392 shares Each RSU represents one share of common stock
Vesting date June 24, 2027 One-year anniversary of the grant date for RSU vesting
Grant price per unit $0.00 Compensation grant, not an open-market purchase
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Annual equity grant financial
"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors."
contingent right financial
"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."
vests financial
"The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027,"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
JOHNSON JOHN
(Last)(First)(Middle)
C/O AXOGEN, INC. 13631 PROGRESS BLVD.
SUITE 400
(Street)
ALACHUA FLORIDA 32615
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Axogen, Inc. [ AXGN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)06/24/2026A4,392 (2) (2)Common Stock4,392$04,392D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
2. Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.
Remarks:
/S/ Marc Began, as attorney-in-fact for John Johnson06/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Axogen (AXGN) director John Johnson report?

Axogen director John Johnson reported receiving an annual equity grant of 4,392 restricted stock units. These RSUs are part of his compensation for Board service and each unit represents a contingent right to one share of Axogen common stock.

Is John Johnson’s Axogen (AXGN) Form 4 a stock purchase or a grant?

The Form 4 reports a grant/award acquisition of restricted stock units, not an open-market stock purchase. The transaction code is “A,” indicating compensation-related equity granted at a price of $0.00 per unit rather than bought in the market.

How many Axogen (AXGN) shares can John Johnson receive from this RSU grant?

John Johnson’s award covers 4,392 restricted stock units, each representing a contingent right to receive one share of Axogen common stock. If fully vested, the grant would deliver 4,392 shares, assuming all vesting conditions are satisfied.

When do John Johnson’s Axogen (AXGN) restricted stock units vest?

The RSUs are scheduled to vest on June 24, 2027, the one-year anniversary of the grant date. Vesting is tied to his continued service as a director on Axogen’s Board through that date, according to the footnote disclosure.

What is the reported value of John Johnson’s Axogen (AXGN) RSU grant?

The equity grant is based on a $185,000 valuation as of the grant date. This valuation determines how many restricted stock units were awarded, resulting in the 4,392 RSUs disclosed for John Johnson’s Board compensation.